NASDAQ:MCRBSeres Therapeutics Stock Price, Forecast & News

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MCRB stock has increased by 77.3% and is now trading at $4.68. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seres Therapeutics.

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Seres Therapeutics.

Seres Therapeutics Inc (NASDAQ:MCRB) announced its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.28) EPS for the quarter, hitting the consensus estimate of ($0.28). The biotechnology company had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.01 million. View Seres Therapeutics' earnings history.

6 Wall Street analysts have issued 1-year price targets for Seres Therapeutics' shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Seres Therapeutics' stock price to reach $7.50 in the next year. This suggests a possible upside of 60.3% from the stock's current price. View analysts' price targets for Seres Therapeutics.

News articles about MCRB stock have trended positive on Saturday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Seres Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutSeres Therapeutics.

Seres Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 5,590,000 shares, an increase of 9.6% from the April 30th total of 5,100,000 shares. Based on an average daily volume of 320,700 shares, the days-to-cover ratio is currently 17.4 days. Currently, 13.1% of the shares of the stock are short sold. View Seres Therapeutics' Current Options Chain.

Some companies that are related to Seres Therapeutics include I-Mab (IMAB), Mersana Therapeutics (MRSN), Karyopharm Therapeutics (KPTI), Tricida (TCDA), Arvinas (ARVN), Kiniksa Pharmaceuticals (KNSA), Phathom Pharmaceuticals (PHAT), Supernus Pharmaceuticals (SUPN), Revance Therapeutics (RVNC), Odonate Therapeutics (ODT), Esperion Therapeutics (ESPR), Cytokinetics (CYTK), Aimmune Therapeutics (AIMT), I-Mab (ARQT) and Phibro Animal Health (PAHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Exelixis (EXEL) and Gilead Sciences (GILD).

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Seres Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (11.83%), Nikko Asset Management Americas Inc. (11.83%), Sumitomo Mitsui Trust Holdings Inc. (11.83%), BlackRock Inc. (5.55%), JPMorgan Chase & Co. (1.44%) and Federated Hermes Inc. (1.42%). Company insiders that own Seres Therapeutics stock include Eric D Shaff, John G Aunins, Marcus Chapman, Noubar Afeyan, Roger Pomerantz and Thomas Desrosier. View institutional ownership trends for Seres Therapeutics.

MCRB stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, AXA, Two Sigma Investments LP, BlackRock Inc., Parametric Portfolio Associates LLC, Morgan Stanley, Jane Street Group LLC, and State Street Corp. View insider buying and selling activity for Seres Therapeutics.

MCRB stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., JPMorgan Chase & Co., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Geode Capital Management LLC, Alliancebernstein L.P., and Two Sigma Advisers LP. View insider buying and selling activity for Seres Therapeutics.

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MCRB stock can currently be purchased for approximately $4.68.

Seres Therapeutics has a market capitalization of $339.77 million and generates $34.51 million in revenue each year. The biotechnology company earns $-70,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe.

The official website for Seres Therapeutics is www.serestherapeutics.com.

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]